Related Experiment Video
Updated: Jul 8, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
[Chromosomal structural changes in patients with myelodysplastic syndrome]
Yang Yu1, Xu-ping Liu, Shi-he Liu
1Institute of Hematology, State Key Laboratory of Experiment Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Zhonghua Yi Xue Za Zhi
|January 3, 2008
Summary
This study analyzes the clinical and laboratory features of myelodysplastic syndromes (MDS) with chromosomal structural changes. Specific genetic alterations like i(17)(q10) and t(1;3)(p36;q21) may represent unique MDS subsets with distinct prognoses.
Area of Science:
- Hematology
- Cytogenetics
- Oncology
Context:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Chromosomal abnormalities are common in MDS and influence prognosis.
- Understanding specific structural changes is crucial for accurate classification and treatment.
Purpose:
- To investigate the clinical and laboratory characteristics of myelodysplastic syndromes (MDS) associated with specific chromosomal structural changes.
- To reclassify MDS cases according to WHO criteria based on cytogenetic data.
- To identify potential new clinical-pathologic subsets within MDS.
Summary:
- A retrospective analysis of 50 MDS patients with chromosomal structural changes revealed an incidence of 7.4%.
- Frequently observed changes include i(17)(q10), t(1;3)(p36;q21), der(1;7)(q10;p10), and der(22).
- These genetic alterations correlate with distinct clinical features, such as anemia severity, prognosis, and specific morphological dysplasia patterns.
Impact:
- Identifies i(17)(q10), t(1;3)(p36;q21), and der(1;7)(q10;p10) as potentially novel clinical-pathologic subsets in MDS.
- Highlights the prognostic significance of specific chromosomal aberrations in MDS.
- Provides a foundation for further research into the classification and management of MDS with complex cytogenetics.
Related Concept Videos
01:17Karyotyping
Describing the number and physical features of chromosomes can reveal abnormalities that underlie genetic diseases. This description is facilitated by special staining techniques that produce a particular banding pattern on each chromosome. State-of-the-art techniques make this approach even more powerful, enabling the detection of individual genes that cause disease.A Simple Chromosome Staining Technique Provides Valuable Scientific InsightSome genetic diseases can be detected by looking at...
01:32Chromatin Modification in iPS Cells
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...